CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 570
- 试验地点
- 72
- 主要终点
- Patient-reported Quality of Life as Measured by the Physical Function Scale of the European Organization for Research and Treatment of Cancer Quality-of-Life-Questionnaire-Core-30 (EORTC QLQ-C30)
研究概览
简要总结
Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to fill these critical evidence gaps, change care pathways for the management of non-muscle-invasive bladder cancer (NMIBC), and provide for personalized, patient-centered care. The purpose of CISTO is to conduct a large prospective study that directly compares the impact of medical management versus bladder removal in recurrent high-grade NMIBC patients with Bacillus Calmette-Guerin (BCG) failure on clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).
详细描述
Most bladder cancer patients (74%) present with NMIBC where the cancer is limited to the lining or support layer of the bladder. High-grade NMIBC is treated initially with endoscopic resection and intravesical immunotherapy, followed by bladder instillations of BCG. Most patients with high-risk, high-grade NMIBC are able to retain their bladders and avoid more invasive treatments. However, 24-61% of patients will have their cancers recur within 12 months of treatment with BCG (BCG failures), and they have limited treatment options. National guidelines recommend consideration between two alternatives: additional medical management and radical cystectomy (removal of the bladder). Selecting between these options involves weighing the risk of progression of bladder cancer and loss of a window of potential cure versus the risk of morbidity and loss of quality of life (QOL) with bladder removal. This complex decision-making engages patients and their caregivers, who may be impacted by the urinary, sexual, and bowel dysfunctions that can occur with NMIBC treatment.
The investigators will evaluate this research question on a large scale in real world practice settings including academic and community-based practices and examine patient-centered outcomes. The investigators have engaged stakeholders with diverse perspectives relevant to this research question, including patients, caregivers, national patient advocacy organizations, national medical specialty organizations, guideline developers, health care payers, and industry. By engaging broad expertise relevant to this research question, the investigators will ensure that the study results will help NMIBC patients whose cancer recurs after BCG treatment make more informed decisions that improve the health outcomes that are important to them.
CISTO is an observational study that will not affect the treatment that patients chose. Patient surveys will occur at study entry and at follow-up assessments for up to four years. There will also be a qualitative sub-study that will include interviews of approximately 50 patients and 25 caregivers recruited from the observational cohort study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient Eligibility, Inclusion Criteria:
- •Adult 18 years of age or older; and
- •Presenting with high-grade NMIBC established by anatomic pathology as tumor stage classification Tis, Ta, or T1, and with:
- •Pathology documentation from any hospital/clinic/medical center, and
- •More than 50% urothelial carcinoma component in the specimen
- •History of high-grade NMIBC established by anatomic pathology as tumor stage classification Tis, Ta, or T1; and
- •Attempted or received induction BCG (at least 3 out of 6 instillations) at any point in time; and
- •In the previous 12 months, received at least one instillation of any intravesical agent (induction or maintenance) or one administration of systemic therapy for NMIBC treatment.
- •Patient Eligibility,
排除标准
- •Any plasmacytoid or small cell (neuroendocrine) component in the pathology (past or current presentation);
- •Previous history of cystectomy or radiation therapy for bladder cancer;
- •Previous history of muscle-invasive bladder cancer or metastatic bladder cancer;
- •Any history of upper tract urothelial carcinoma;
- •Incarcerated in a detention facility or in police custody (patients wearing a monitoring device can be enrolled) at baseline/screening;
- •Contraindication to radical cystectomy (e.g., American Society of Anesthesiologists (ASA) physical status of 4, patient not considered a radical cystectomy candidate due to comorbidity);
- •Contraindication to medical therapy (i.e., intolerant of all medical therapies);
- •Unable to provide written informed consent in English;
- •Unable to be contacted for research surveys;
- •Planning to participate in a Phase I or Phase II interventional clinical trial for NMIBC (unless in the control/comparator arm of a Phase II trial) or any blinded interventional trial for NMIBC.
结局指标
主要结局
Patient-reported Quality of Life as Measured by the Physical Function Scale of the European Organization for Research and Treatment of Cancer Quality-of-Life-Questionnaire-Core-30 (EORTC QLQ-C30)
时间窗: 60 months after enrollment
Patient-reported quality of life is measured by the EORTC QLQ-C30 Physical Function scale. The scale ranges in score from 0 to 100, with higher function scores indicating better health. Scale score is calculated by transforming individual item scores into a 0 to 1 scale, taking the mean, and multiplying by 100. Each scale requires responses for at least 50% of the items in order to be calculated.
次要结局
- Patient Self-reported Urinary Health as Measured by the Bladder Cancer Index Urinary Summary Score(60 months after enrollment)
- Patient Self-reported Sexual Health as Measured by the Bladder Cancer Index Sexual Summary Score(60 months after enrollment)
- Patient Self-reported Bowel Health as Measured by the Bladder Cancer Index Bowel Summary Score(60 months after enrollment)
- Patient Self-reported Financial Distress as Measured by the Comprehensive Score for Financial Toxicity (COST)(60 months after enrollment)
- Patient-reported Anxiety as Measured by the Patient Reported Outcome Measurement Information System (PROMIS) Short Form v1.0 - Anxiety 4a(60 months after enrollment)
- Patient-reported Depression as Measured by the Patient Reported Outcome Measurement Information System (PROMIS) Short Form v1.0 - Depression 4a(60 months after enrollment)
- Patient-reported Generic Quality of Life as Measured by the EuroQoL EQ-5D-5L(60 months after enrollment)
- Patient Recurrence-free Survival(60 months after diagnosis of recurrent high-grade non-muscle invasive bladder cancer)
- Patient Metastasis-free Survival(60 months after diagnosis of recurrent high-grade non-muscle invasive bladder cancer)
- Patient Progression-free Survival(60 months after diagnosis of recurrent high-grade non-muscle invasive bladder cancer)
- Patient Bladder Cancer-specific Survival(60 months after diagnosis of recurrent high-grade non-muscle invasive bladder cancer)
- Patient Overall Survival(60 months after diagnosis of recurrent high-grade non-muscle invasive bladder cancer)
研究者
John Gore
Associate Professor, School of Medicine: Urology
University of Washington